Connor Clark & Lunn Investment Management Ltd. Buys New Stake in Dynavax Technologies Corporation $DVAX

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 336,951 shares of the biopharmaceutical company's stock, valued at approximately $4,370,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.28% of Dynavax Technologies at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. lifted its stake in shares of Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Dynavax Technologies during the 1st quarter valued at $30,000. GF Fund Management CO. LTD. bought a new stake in Dynavax Technologies during the 4th quarter valued at $35,000. GAMMA Investing LLC raised its holdings in shares of Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 3,627 shares in the last quarter. Finally, Moloney Securities Asset Management LLC bought a new stake in shares of Dynavax Technologies in the 1st quarter valued at about $131,000. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Stock Up 0.4%

NASDAQ:DVAX traded up $0.05 during mid-day trading on Monday, hitting $10.84. 321,540 shares of the company's stock traded hands, compared to its average volume of 2,079,008. The company has a market capitalization of $1.27 billion, a P/E ratio of -23.55 and a beta of 1.09. Dynavax Technologies Corporation has a twelve month low of $9.22 and a twelve month high of $14.63. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The company has a fifty day moving average of $10.57 and a 200 day moving average of $11.47.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. The business had revenue of $95.44 million for the quarter, compared to analyst estimates of $87.55 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. On average, analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on DVAX. Wall Street Zen raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. JMP Securities boosted their price target on Dynavax Technologies from $31.00 to $32.00 and gave the stock a "market outperform" rating in a research report on Friday, August 8th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.